Zhang Jiandong, Rudemiller Nathan P, Patel Mehul B, Karlovich Norah S, Wu Min, McDonough Alicia A, Griffiths Robert, Sparks Matthew A, Jeffs Alexander D, Crowley Steven D
Division of Nephrology, Department of Medicine, Duke University and Durham VA Medical Centers, Durham, NC 27710, USA.
Department of Cell and Neurobiology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
Cell Metab. 2016 Feb 9;23(2):360-8. doi: 10.1016/j.cmet.2015.11.013. Epub 2015 Dec 17.
Hypertension is among the most prevalent and catastrophic chronic diseases worldwide. While the efficacy of renin angiotensin system (RAS) blockade in lowering blood pressure illustrates that the RAS is broadly activated in human hypertension, the frequent failure of RAS inhibition to prevent or reverse hypertensive organ damage highlights the need for novel therapies to combat RAS-dependent hypertension. We previously discovered elevated levels of the macrophage cytokine IL-1 in the kidney in a murine model of RAS-mediated hypertension. Here we report that IL-1 receptor (IL-1R1) deficiency or blockade limits blood pressure elevation in this model by mitigating sodium reabsorption via the NKCC2 co-transporter in the nephron. In this setting, IL-1R1 activation prevents intra-renal myeloid cells from maturing into Ly6C(+)Ly6G(-) macrophages that elaborate nitric oxide, a natriuretic hormone that suppresses NKCC2 activity. By revealing how the innate immune system regulates tubular sodium transport, these experiments should lead to new immunomodulatory anti-hypertensive therapies.
高血压是全球最常见且危害极大的慢性疾病之一。虽然肾素血管紧张素系统(RAS)阻断在降低血压方面的功效表明RAS在人类高血压中广泛激活,但RAS抑制未能预防或逆转高血压器官损伤的情况屡见不鲜,这凸显了对抗RAS依赖性高血压的新型疗法的必要性。我们之前在RAS介导的高血压小鼠模型中发现,肾脏中巨噬细胞细胞因子白细胞介素-1(IL-1)水平升高。在此我们报告,IL-1受体(IL-1R1)缺陷或阻断通过减轻肾单位中通过NKCC2共转运体的钠重吸收来限制该模型中的血压升高。在这种情况下,IL-1R1激活可阻止肾内髓样细胞成熟为可产生一氧化氮的Ly6C(+)Ly6G(-)巨噬细胞,一氧化氮是一种抑制NKCC2活性的利钠激素。通过揭示先天免疫系统如何调节肾小管钠转运,这些实验应能带来新的免疫调节性抗高血压疗法。